Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy

BACKGROUND: Prognostic studies of insulin-like growth factor-1 receptor(IGF-1R) inhibitors in cancer therapy had promising results in infratests, which exhibited that IGF-1R signalling was crucial in cancer cells growth. However, the conclusion of later clinical trials revealed a dim future for IGF-...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncotarget
Main Authors: Qu, Xiao, Wu, Zhinan, Dong, Wei, Zhang, Tiehong, Wang, Liguang, Pang, Zhaofei, Ma, Wei, Du, Jiajun
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2017
主題:
Review
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5438747/
https://ncbi.nlm.nih.gov/pubmed/28427155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15704
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍